1-苯基-2-(吡啶-2-基)乙胺
中文名称 | 1-苯基-2-(吡啶-2-基)乙胺 |
---|---|
中文同义词 | 1-苯基-2-(吡啶-2-基)乙胺;1-苯基-2-(吡啶-2-基)乙烷-1-胺;(RAC)-拉尼西明;化合物 (RAC)-LANICEMINE |
英文名称 | 1-phenyl-2-(pyridin-2-yl)ethanamine |
英文同义词 | 1-phenyl-2-(pyridin-2-yl)ethanamine;1-Phenyl-2-(2-pyridinyl)ethanamine;rac-Lanicemine 2HCl;(Rac)-Lanicemine |
CAS号 | 61890-25-3 |
分子式 | C13H14N2 |
分子量 | 198.26 |
EINECS号 | |
相关类别 | |
Mol文件 | 61890-25-3.mol |
结构式 |
1-苯基-2-(吡啶-2-基)乙胺 性质
沸点 | 160 °C(Press: 2 Torr) |
---|---|
密度 | 1.097±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:100 mg/mL(504.39 mM) |
形态 | 液体 |
酸度系数(pKa) | 8.29±0.10(Predicted) |
颜色 | 无色至浅黄 |
(Rac)-Lanicemine ((Rac)-AZD6765) 是 Lanicemine 的外消旋体。Lanicemine (AZD6765) 是一种低捕获的 NMDA 受体拮抗剂,Ki 为 0.56-2.1 μM。CHO 和爪蟾卵母细胞中,IC50 分别为 4-7 μM 和 6.4 μM。具有抗抑郁作用。
NMDA receptor
Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine.
Animal Model: | Male Sprague-Dawley rats |
Dosage: | 3, 10 or 30 mg/kg |
Administration: | Intraperitoneal |
Result: | Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-108235B | (Rac)-Lanicemine | 5 mg | 312元 | |
2024/08/19 | HY-108235B | 1-苯基-2-(吡啶-2-基)乙胺 (Rac)-Lanicemine | 61890-25-3 | 10mg | 500元 |